"10.1371_journal.pone.0076907","plos one","2013-10-09T00:00:00Z","Sofia Sisay; Gareth Pryce; Samuel J Jackson; Carolyn Tanner; Ruth A Ross; Gregory J Michael; David L Selwood; Gavin Giovannoni; David Baker","Neuroimmunology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; School of Medical Science, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom; Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Biological and Medical Chemistry, the Wolfson Institute for Biomedical Research, University College London, London, United Kingdom","Conceived and designed the experiments: SS GP SJJ RAR GJM DLS GG DB. Performed the experiments: SS GP SJJ CT DLS DB. Analyzed the data: SS GP CT RAR DB. Contributed reagents/materials/analysis tools: SS GP RAR DLS DB. Wrote the manuscript: SS GP DB. Initial Concepts: DB GP SJJ DLS. Obtained funding: DB GG SJJ DLS. Screening mice: SS SJJ GJM GP DB. In vivo Experiments: SS GP DB. Immunoassays: SS DB. Vas Deferens Assays: CT RAR. Draft Initial Manuscript: SS GP DB. Final Manuscript: SS GP SJJ CT RAR GJM DLS GG DB.","Some of authors are named inventors on a patent (Masahiro O, Selwood D, Visintin C, Baker D, Pryce G. Modulators of cannabinoid receptors. WO2004100893) related to (R)3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)Â benzamide. Selwood D,Baker D and Giovannoni G are shareholders and consultants to Canbex Ltd, which is University Spin-out Company, aimed at exploiting the intellectual property within W02004100893. Pryce G is a shareholder from Canbex Ltd. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","10","Sofia Sisay","SS",9,TRUE,8,6,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
